Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

Therapeutic drug monitoring of ciclosporin

A. Johnston, D. W. Holt

Ann Transplant 2008; 13(1): 24-24 :: ID: 880178


There can be no doubt that the introduction of ciclosporin for the prevention of rejection of transplanted organs, in the early nineteen eighties, revolutionised transplantation. However, the inability to define an individual's optimal ciclosporin dose, one that maximises effi cacy while at the same time minimises toxicity, has been a problem. For this reason therapeutic drug monitoring (TDM) of ciclosporin has become an established part of the routine clinical management of patients receiving the drug after organ transplantation. The use of drug concentrations as a means of optimising ciclosporin dose has evolved in a haphazard and ad hoc fashion. Initially plasma or serum blood concentrations were measured using assay techniques that were not specific for the parent compound. Over time it was realised that neither plasma nor serum were appropriate matrices as the temperature, and hence time, of separation caused major changes in the partitioning of ciclosporin into red cells. Therefore whole blood, with EDTA anticoagulation, became the matrix of choice for the measurement of the drug. At the same time, it was becoming apparent that variations in the metabolite to parent drug ratio with time after transplant, transplant type, concurrent disease and even during rejection made the use of non-specific measurements of drug concentration unreliable and a series of specific, or at least "more specific", assay methodologies were developed. Therefore measurement of ciclosporin in whole blood with a specific assay method became the agreed consensus for all transplant types. However, there is no consensus on whether for the best results a target value or range of values should be used, what the target(s) should be, how these should be adjusted to allow for transplant type, co-medication, time after transplantation, concomitant disease, race, sex etc. Added to which there is still debate about whether pre-dose (trough or C0) or another timed sample, such as two hours after drug administration (C2), or area under the concentration time-curve (AUC) result in the best patient outcomes. These questions may only be answered, and the relative merits of different sampling times decided, by prospective testing in double blind trials. Therapeutic drug monitoring, like any other medical intervention, needs to be evaluated in terms of cost-effectiveness, feasibility and clinical relevance, with the ultimate goal of improving patient and graft survival.

Keywords: thyroid cancer metestasis, Transplantation, therapeutic drug monitoring


In Press

20 Jan 2022 : Original article  

Impact on Waitlist Outcomes from Changes in the Medical Eligibility of Candidates for Simultaneous Liver-Ki...

Ann Transplant In Press; DOI: 10.12659/AOT.934850  

19 Jan 2022 : Original article  

Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in He...

Ann Transplant In Press; DOI: 10.12659/AOT.933420  

18 Jan 2022 : Original article  

PLGA+Fe₃O₄+PFP Nanoparticles Drug-Delivery Demonstrates Potential Anti-Tumor Effects on Tumor Cells

Ann Transplant In Press; DOI: 10.12659/AOT.933246  

17 Jan 2022 : Original article  

Impact of Thyroid Incidentaloma on Liver Transplant: A Study of 1010 Recipients at a Single Center

Ann Transplant In Press; DOI: 10.12659/AOT.934988  

Most Viewed Current Articles

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

22 Dec 2021 : Original article  

Comparison of Coronary Artery Calcium Scoring with Dobutamine Stress Echo for Detection of Coronary Artery ...

DOI :10.12659/AOT.934163

Ann Transplant 2021; 26:e934163

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

01 Dec 2021 : Original article  

Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-S...

DOI :10.12659/AOT.934175

Ann Transplant 2021; 26:e934175

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358